Cargando…

P10 Impact of miniaturization and early readout on antimicrobial susceptibility tests

BACKGROUND: New technologies offer the promise of faster, more accessible antibiotic susceptibility testing. UK policy includes the development and introduction of innovative diagnostics to tackle antimicrobial resistance, and whilst many new technologies are emerging, we still have limited evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Needs, Sarah, Hayward, Jessica, Kidd, Stephen, Edwards, Al
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266161/
http://dx.doi.org/10.1093/jacamr/dlad066.014
_version_ 1785058687918800896
author Needs, Sarah
Hayward, Jessica
Kidd, Stephen
Edwards, Al
author_facet Needs, Sarah
Hayward, Jessica
Kidd, Stephen
Edwards, Al
author_sort Needs, Sarah
collection PubMed
description BACKGROUND: New technologies offer the promise of faster, more accessible antibiotic susceptibility testing. UK policy includes the development and introduction of innovative diagnostics to tackle antimicrobial resistance, and whilst many new technologies are emerging, we still have limited evidence of their performance. Many of these emerging technologies are changing two core aspects of antimicrobial susceptibility tests (AST). Firstly, using microfluidic platforms to miniaturize standard antibiotic susceptibility testing and secondly measuring susceptibility at earlier timepoints, here, we report a comprehensive assessment of 1-mL volume broth microdilution with an early endpoint readout, proving that miniaturization and earlier timepoints of conventional antibiotic susceptibility testing is feasible and accurate. METHODS: The test measures bacterial growth in 1-mL capillaries in the presence of the metabolic dye resazurin. All other aspects of the test remain standard. Images of the capillaries are taken every 5 minutes over 18 h to determine accuracy at different timepoints during incubation at 37°C. Over a total of 3 sites in the UK, Spain and Thailand, we have tested 367 isolates from clinical samples for 8–17 antibiotics. RESULTS: Preliminary data shows that for 99 Gram-negative isolates tested in Thailand, after 6-h incubation, accuracy for antibiotics is as follows: cefotaxime 96%, ceftazidime 92%, meropenem 93%, amikacin 94%, amoxicillin–clavulanic acid 79%, cefuroxime 97%, cefoxitin 80%, ciprofloxacin 84%, gentamicin 93% and trimethoprim 97%. Further testing is ongoing, and isolates from urine samples are currently being collected from Basingstoke and North Hampshire hospital to expand the type of organism tested. CONCLUSIONS: Unlike many microfluidic systems, the dip and test microcapillary–based broth microdilution test is manufactured in bulk, allowing rapid and testing of large sample sets with minimal investment. An understanding of the effect of miniaturization is vital to developers of microfluidic phenotypic antibiotic susceptibility tests and can provide confidence in emerging systems.
format Online
Article
Text
id pubmed-10266161
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102661612023-06-15 P10 Impact of miniaturization and early readout on antimicrobial susceptibility tests Needs, Sarah Hayward, Jessica Kidd, Stephen Edwards, Al JAC Antimicrob Resist Abstracts BACKGROUND: New technologies offer the promise of faster, more accessible antibiotic susceptibility testing. UK policy includes the development and introduction of innovative diagnostics to tackle antimicrobial resistance, and whilst many new technologies are emerging, we still have limited evidence of their performance. Many of these emerging technologies are changing two core aspects of antimicrobial susceptibility tests (AST). Firstly, using microfluidic platforms to miniaturize standard antibiotic susceptibility testing and secondly measuring susceptibility at earlier timepoints, here, we report a comprehensive assessment of 1-mL volume broth microdilution with an early endpoint readout, proving that miniaturization and earlier timepoints of conventional antibiotic susceptibility testing is feasible and accurate. METHODS: The test measures bacterial growth in 1-mL capillaries in the presence of the metabolic dye resazurin. All other aspects of the test remain standard. Images of the capillaries are taken every 5 minutes over 18 h to determine accuracy at different timepoints during incubation at 37°C. Over a total of 3 sites in the UK, Spain and Thailand, we have tested 367 isolates from clinical samples for 8–17 antibiotics. RESULTS: Preliminary data shows that for 99 Gram-negative isolates tested in Thailand, after 6-h incubation, accuracy for antibiotics is as follows: cefotaxime 96%, ceftazidime 92%, meropenem 93%, amikacin 94%, amoxicillin–clavulanic acid 79%, cefuroxime 97%, cefoxitin 80%, ciprofloxacin 84%, gentamicin 93% and trimethoprim 97%. Further testing is ongoing, and isolates from urine samples are currently being collected from Basingstoke and North Hampshire hospital to expand the type of organism tested. CONCLUSIONS: Unlike many microfluidic systems, the dip and test microcapillary–based broth microdilution test is manufactured in bulk, allowing rapid and testing of large sample sets with minimal investment. An understanding of the effect of miniaturization is vital to developers of microfluidic phenotypic antibiotic susceptibility tests and can provide confidence in emerging systems. Oxford University Press 2023-06-14 /pmc/articles/PMC10266161/ http://dx.doi.org/10.1093/jacamr/dlad066.014 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Needs, Sarah
Hayward, Jessica
Kidd, Stephen
Edwards, Al
P10 Impact of miniaturization and early readout on antimicrobial susceptibility tests
title P10 Impact of miniaturization and early readout on antimicrobial susceptibility tests
title_full P10 Impact of miniaturization and early readout on antimicrobial susceptibility tests
title_fullStr P10 Impact of miniaturization and early readout on antimicrobial susceptibility tests
title_full_unstemmed P10 Impact of miniaturization and early readout on antimicrobial susceptibility tests
title_short P10 Impact of miniaturization and early readout on antimicrobial susceptibility tests
title_sort p10 impact of miniaturization and early readout on antimicrobial susceptibility tests
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266161/
http://dx.doi.org/10.1093/jacamr/dlad066.014
work_keys_str_mv AT needssarah p10impactofminiaturizationandearlyreadoutonantimicrobialsusceptibilitytests
AT haywardjessica p10impactofminiaturizationandearlyreadoutonantimicrobialsusceptibilitytests
AT kiddstephen p10impactofminiaturizationandearlyreadoutonantimicrobialsusceptibilitytests
AT edwardsal p10impactofminiaturizationandearlyreadoutonantimicrobialsusceptibilitytests